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DC NK lectin group receptor-1 (DNGR-1, also known as CLEC9A) is a C-type lectin receptor
expressed by mouse CD8a
1 DC and by their putative equivalents in human. DNGR-1
senses necrosis and regulates CD8
1 T-cell cross-priming to dead-cell-associated antigens.
In addition, DNGR-1 is a target for selective in vivo delivery of antigens to DC and the
induction of CD8
1 T-cell and Ab responses. In this study, we evaluated whether DNGR-1
targeting can be additionally used to manipulate antigen-speciﬁc CD4
1 T lymphocytes.
Injection of small amounts of antigen-coupled anti-DNGR-1 mAb into mice promoted MHC
class II antigen presentation selectively by CD8a
1 DC. In the steady state, this was sufﬁ-
cient to induce proliferation of antigen-speciﬁc naı ¨ve CD4
1 T cells and to drive their
differentiation into Foxp3
1 regulatory lymphocytes. Co-administration of adjuvants
prevented this induction of tolerance and promoted immunity. Notably, distinct adjuvants
allowed qualitative modulation of CD4
1 T-cell behavior: poly I:C induced a strong IL-12-
independent Th1 response, whereas curdlan led to the priming of Th17 cells. Thus,
antigen targeting to DNGR-1 is a versatile approach for inducing functionally distinct CD4
1
T-cell responses. Given the restricted pattern of expression of DNGR-1 across species, this
strategy could prove useful for developing immunotherapy protocols in humans.
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Introduction
Regulating the T-cell compartment is the principal function of DC
and therefore, manipulation of DC offers great promise for immune
intervention [1, 2]. Numerous studies have focused on the
therapeutic potential of ex-vivo-generated DC that are subsequently
infused into patients [2]. An alternative approach consists of Ab-
mediated targeting of antigens to endocytic receptors expressed by
DC in vivo [3, 4]. In mice, this method can elicit powerful cellular
and humoral responses, beneﬁcial in models of cancer or infection
[5–11]. Conversely, it can also lead to antigen-speciﬁc tolerance,
useful for limiting autoimmune diseases or allograft rejection [5, 8,
12–14]. Whether antigen targeting to DC results in tolerance or
immunity depends on the nature of the targeting Ab, antigen dose,
co-administered adjuvants, immunological readout used to
measure response, and importantly, the receptor used for targeting
[3, 4]. Ideally, the latter should be restricted in expression to DC to
allow for focused antigen delivery, and should additionally be
capable of mediating endocytosis of bound Ab–antigen conjugates
and delivering these to antigen processing pathways. In addition,
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its targeting by antibodies should not result in overwhelming
delivery of signals that instruct DC to prime particular types of
immune responses. Antigen targeting to such ‘‘neutral’’ receptors
can then be combined with deﬁned immunomodulators to favor
speciﬁc immune outcomes, ranging from immunological tolerance
to different kinds of immunity.
DC comprise multiple subsets that may be specialized to
perform distinct and, sometimes, opposing functions [15, 16].
Thus, another consideration in targeting approaches is whether it
might be preferable to direct antigens to a single DC subset or to
multiple subtypes. Of the large panel of endocytic surface mole-
cules tested as targeting receptors to date, many are expressed by
multiple DC subsets and by other populations of hematopoietic
and/or non-hematopoietic cells [3, 4]. In search for receptors
restricted in expression to speciﬁc DC subsets, we identiﬁed a novel
endocytic C-type lectin receptor that we named DC NK lectin group
receptor-1 (DNGR-1) [9, 17, 18]. In mice, DNGR-1 (also known as
CLEC9A) is expressed at high level by the CD8a
1 subset and at low
level by plasmacytoid DC (pDC) [9, 17, 18]. In our studies, mouse
DNGR-1 was not detected on other leukocytes, although others
have reported low levels of expression on a subset of B cells [17].
Interestingly, DNGR-1 expression is also very restricted to DC in
human PBMC as it is detected almost exclusively on lineage-
negative BDCA-3
1 cells [9, 17, 18], a subtype of DC proposed to
constitute the functionally equivalent of the mouse CD8a
1 DC
population [19]. DNGR-1 binds to an unidentiﬁed ligand(s)
exposed in necrotic cells and is involved in crosspresentation of
dead-cell-associated antigens [20]. In line with this role, we found
that antigens targeted to mouse DNGR-1 via antibodies were
efﬁciently crosspresented by CD8a
1 DC to CD8
1 T cells [9, 17].
Notably, when given with adjuvants, anti-DNGR-1 antigen conju-
gates induce effective CTL responses that protect mice from tumor
challenge in both prophylactic and therapeutic settings [9].
It has recently been shown by Caminschi et al. that antigen
targeting to DNGR-1 can additionally promote MHC class II
presentation and T-cell-dependent Ab production [17]. In
contrast to CTL priming [9], the Ab responses seen did not
require co-administration of adjuvant, suggesting that DNGR-1
targeting to DC might generate intrinsic signals that favor CD4
1
but not CD8
1 T-cell priming [17]. In this study, we conﬁrm that
antigens targeted to DNGR-1 in the steady state can be presented
on MHC class II molecules, and we show that this presentation is
restricted to CD8a
1 DC. However, we ﬁnd that, in the absence of
adjuvant, Ab responses are weak and show that this form of
antigen targeting does not inevitably lead to CD4
1 T-cell priming
but, rather, can be used to favor the conversion of antigen-
speciﬁc naı ¨ve CD4
1 T cells into Foxp3
1 suppressive cells. In
contrast, in the presence of adjuvants, the same targeting
approach promotes the development of potent Ab and Th1 or
Th17 CD4
1 T-cell responses. Thus, DNGR-1 acts predominantly
as a ‘‘neutral’’ receptor, and antigen targeting to this receptor
combined with appropriate immunomodulators can be used to
promote a wide range of responses, from dominant tolerance to
qualitatively distinct types of immunity.
Results
Anti-DNGR-1 mAb selectively and rapidly targets
CD8a
1 and pDC in mice
To mark DNGR-1
1 cells in vivo, mice were injected i.v. with
ﬂuorophore-labeled anti-DNGR-1 or isotype-matched control
mAb. We then analyzed the labeling of different cell types in
secondary lymphoid tissues at time points ranging from 5 to
120min post injection. In mice injected with anti-DNGR-1 mAb
but not with the isotype control mAb, we observed rapid and
bright staining of the CD8a
1CD11c
1 population (Supporting
Information Fig. 1A and C). In agreement with the previously
described pattern of expression of DNGR-1 [9, 17], we were
unable to detect any labeling of the CD11c
  compartment or
CD4
1 DC, whereas a fraction of pDC was stained, although with
reduced intensity and slower kinetics when compared with
CD8a
1 DC (Supporting Information Fig. 1A, B and 2). Systemic
inﬂammation induced by LPS administration did not change the
pattern of targeting by anti-DNGR-1 mAb (Supporting Informa-
tion Fig. 2). These data conﬁrm that anti-DNGR-1 mAb rapidly
and speciﬁcally targets CD8a
1 DC and, to a lower extent, pDC.
Antigen targeting to DNGR-1 in the steady-state allows
MHC class II presentation by CD8a
1 DC
To test whether DNGR-1 targeting promotes MHC class II antigen
presentation by DC, we covalently conjugated anti-DNGR-1 or
isotype-matched control mAb to the OVA323–339 peptide. We then
injected B6 mice with 2mg of either conjugate and, after 4h,
puriﬁed different subpopulations of splenocytes. To reveal
processed antigen on MHC class II molecules, we cultured
increasing number of cells with CFSE-labeled OVA-speciﬁc
OT-II CD4
1 T lymphocytes for 4–5 days. We only observed
T-cell division with CD11c
1 cells puriﬁed from mice injected with
anti-DNGR-1 mAb (Fig. 1A). Furthermore, among the CD11c
1
cells, only the CD8a
1 fraction was able to induce potent OT-II
proliferation (Fig. 1B and C). Thus, DNGR-1 targeting allows for
MHC class II presentation by CD8a
1 DC in vivo.
MHC class II:peptide complexes generated after targeting to
CD8a
1 DC using DEC205-speciﬁc mAb are not stable with time
[21]. To test whether the same was true when anti-DNGR-1 mAb
was used as vector, we injected B6 mice with OVA323–339-coupled
anti-DNGR1 mAb and analyzed MHC class II presentation by DC
at different time points. Consistent with the kinetics of in vivo
staining, CD8a
1 but not CD8a
  DC were able to efﬁciently
present antigen to OT-II cells as early as 1h after injection
(Fig. 1C). Antigen presentation peaked at 6h but was markedly
reduced by 24h (Fig. 1C). Thus, antigen targeting to CD8a
1
DC using anti-DNGR-1 mAb in the absence of adjuvant leads to
rapid but short-lived antigen presentation on MHC class II
molecules.
To monitor presentation directly in vivo, we transferred CFSE-
labeled OT-II cells and 1 day later, we injected the mice with
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OVA323–339-coupled isotype-matched control, 20mg of OVA (in
the form of egg white [22]; OVAegg) or 1mg of OVA323–339
peptide. Administering antigen in untargeted form led only to
limited proliferation of OT-II cells, while targeting to DNGR-1
resulted in marked cell division and accumulation (Fig. 2A). On a
molar basis, we estimate that targeting to DNGR-1 was 10 to 100
times more efﬁcient at inducing CD4
1 T-cell expansion than
delivery of untargeted antigen. Thus, despite the restriction of
presentation to a short period of time following antigen delivery
(Fig. 1C), DNGR-1 targeting can induce CD4
1 T-cell proliferation
in vivo, as recently reported [17].
Priming of Th1 responses upon antigen targeting to
DNGR-1 under the cover of poly I:C
Injection of anti-DNGR-1 mAb did not lead to any detectable
activation of splenic CD8a
1 DC (not shown). Nevertheless, we
evaluated whether antigen targeting to DNGR-1 could lead to
Figure 1. Antigen targeting to DNGR-1 leads to MHC class II presentation by CD8a
1 DC. (A) B6 mice were injected i.v. with OVA323–339-coupled anti-
DNGR-1 mAb or with a similarly conjugated Ab control. Four hours later, CD11c
  or CD11c
1 splenocytes were isolated and cultured with CFSE-
labeled OT-II cells. OT-II proliferation was assessed by ﬂow cytometry. Representative CFSE proﬁles are shown in the left panel, whereas the
absolute number of divided OT-II cells is represented in the right panel. (B) As in (A) but the CD11c
1 population was further subdivided into CD8a
 
and CD8a
1 fractions. The left panel shows OT-II proliferation induced by CD8a
1 and CD8a
  DC following targeting with anti-DNGR-1 mAb,
whereas the right panel shows absolute number of OT-II cells obtained after culture with CD8a
1 DC isolated from mice injected with PBS, anti-
DNGR-1 or control mAb conjugates. (C) B6 mice were challenged with OVA323–339-coupled anti-DNGR-1 mAb. At the indicated time points after
injection, antigen presentation by CD8a
  (right panel) and CD8a
1 (left and right panel) CD11c
1 cells was determined as described in (A). For each
condition, APC were (A) isolated from two mice and tested separately or (B, C) pooled from two mice and tested in duplicate. Data are the average
of duplicate tests and are representative of (A, B) three or (C) two independent experiments.
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1 T-cell priming in the absence of adjuvant, as recently
suggested [17]. To avoid any contribution from memory or Treg,
we transferred sorted naı ¨ve OT-II lymphocytes into B6 mice. One
day later, the mice were injected with 0.5mgo fO V A 323–339-coupled
anti-DNGR-1 mAb with or without 40mg of poly I:C, a TLR3 and
RIG-I/MDA5 agonist recently described as the most potent Th1-
promoting adjuvant in experiments of antigen targeting to DEC205
[23]. In the absence of poly I:C, we observed CD4
1 T-cell
expansion but no detectable differentiation into Th1, Th2 or
Th17 cells (Fig. 2B and C and data not shown). Consistent with the
absence of immunity in these conditions, the mice did not develop a
strong Ab response to rat IgG following anti-DNGR-1 injection
(Fig. 3A). Low titers of anti-rat antibodies were detected only when
injecting a higher dose of anti-DNGR-1 mAb (Fig. 3C), matching
the one used in a previous report [17]. However, the anti-rat IgG
response seen with anti-DNGR-1 alone was dwarfed by that which
could be induced by co-administration of poly I:C (Fig. 3C). Poly
I:C additionally led to increased expression of MHC class II and co-
stimulatory molecules on CD8a
1 DC (not shown) and strongly
boosted the expansion of OT-II cells induced by the Ab–antigen
Figure 2. Naı ¨ve CD4
1 T lymphocytes differentiate into Th1 cells following antigen targeting to DNGR-1 in the presence of poly I:C. (A) B6 hosts were
infused with CFSE-labeled naı ¨ve B6.SJL OT-II cells and injected i.v. with either 0.5mgO V A 323–339-coupled anti-DNGR-1 mAb (a-DNGR-1), 20mg OVAegg, 1mg
OVA323–339 peptide, 5mgO V A 323–339-coupled isotype-matched control or PBS. Five days later, OT-II proliferation was assessed by ﬂow cytometry. Sample
acquisition was normalized by time. Bar indicates percentage of divided cells. The division index (Div. Ind.) was determined using the ‘‘proliferation’’
platform of FlowJo. Data are representative of two independent experiments. (B–D) CFSE-labeled naı ¨ve B6.SJL OT-II cells were adoptively transferred into
B6 hosts. One day later, mice were injected in the footpad with 0.5mgo fO V A 323–339-coupled anti-DNGR-1 mAb or with a similarly conjugated control (Iso)
in the presence/absence of poly I:C. 4–6 days later, OT-II expansion was determined by CFSE dilution and Th1 differentiation was monitored by
intracellular IFN-g staining. (B) Representative ﬂow cytometry proﬁles are shown. (C, D) Data are the mean7SEM of three independent replicates from a
single experiment representative of at least three independent experiments. (E) CFSE-labeled naı ¨ve OT-II cells were transferred into either WTor DNGR-1
KO B6 hosts. Mice were then challenged and the CD4
1 T-cell response analyzed as described in (B). Data are the mean7SEM of three independent
replicates from a single experiment representative of two. The p-values were determined using unpaired Student’s t-test (p o 0.01; p o 0.001).
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differentiation of naı ¨ve T cells into Th1 effectors, as shown by
IFN-g staining after acute ex vivo restimulation with OVA323–339
peptide (Fig. 2B, C, E). Demonstrating the speciﬁcity of the
targeting, no T-cell expansion, Th1 priming or anti-rat IgG response
was observed when an isotype-matched control mAb was used
(Fig. 2B–D and 3A) or when anti-DNGR-1 conjugates were injected
into clec9a
egfp/egfp (‘‘DNGR-1 knockout’’; DNGR-1 KO) mice (Fig. 2E
and 3B). Th1 differentiation could also be induced with other
adjuvants such as anti-CD40 mAb or CpG-containing DNA
oligonucleotides (not shown) and could be reproduced in a
different adoptive transfer model (Supporting Information
Fig. 3). Finally, although CD8a
1 DC can produce IL-12 in response
to innate stimuli, such as poly I:C, identical Th1 responses were
seen in WT and IL-12 p40 KO hosts (Supporting Information
Fig. 3), conﬁrming that Th1 priming to antigens presented by
CD8a
1 DC is not dependent on IL-12p70 or IL-23 [10].
Differential programming of CD8a
1 DC by adjuvants
leads to differential polarization of CD4
1 T cells
DC activated by curdlan, a b-(1, 3)-glucan that acts as a selective
Dectin-1 agonist, can steer CD4
1 T-lymphocyte differentiation
into Th17 cells [24]. As Dectin-1 is expressed by CD8a
1 DC [25],
we tested whether curdlan could serve as an adjuvant for Th17
priming when antigen was targeted to DNGR-1. B6 hosts received
naı ¨ve OT-II cells and 1 day later, they were challenged with
OVA323–339-coupled anti-DNGR-1 mAb together with curdlan or
poly I:C. After 5 days, we analyzed OT-II proliferation and
differentiation into cytokine-producing cells by ﬂow cytometry
and ELISA. Although the use of poly I:C as adjuvant induced a
high frequency of IFN-g
1 OT-II cells and copious secretion of
IFN-g upon restimulation, curdlan led to minimal differentiation
of naı ¨ve OT-II cells into Th1 effectors (Fig. 4A and B). Instead, in
mice receiving OVA323–339-coupled anti-DNGR-1 mAb together
with curdlan, OT-II cells differentiated preferentially into IL-17-
producing T cells (Fig. 4A and C). These results indicate that
DNGR-1 targeting can be harnessed to prime a Th17 response.
Targeting antigen to DNGR-1 in non-inﬂammatory
conditions can lead to Treg differentiation
In non-inﬂammatory conditions, antigen presentation by DC can
promote differentiation of naı ¨ve T cells into Treg [12]. To evaluate
whether antigen targeting to DNGR-1 could promote Treg
conversion, we adoptively transferred naı ¨ve OT-II lymphocytes
Figure 3. DNGR-1 targeting leads to limited antigen-speciﬁc Ab production in the absence of adjuvant WT (A–C) or DNGR-1 KO (B) mice were
injected with 0.5mg (A, B) or with the indicated amounts (C) of anti-DNGR-1 or isotype-matched control mAb in the presence/absence of 40mgo f
poly I:C. Anti-rat IgG serum Ab titers were determined (A, B) at the indicated time points or (C) 20 days after immunization. Data are the mean7SD
of three mice from one experiment representative of two.
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of OVA323–339-coupled anti-DNGR-1 mAb, alone or in combination
with poly I:C. As before, injection of increasing amounts of anti-
DNGR-1 mAb led to dose-dependent expansion of the OT-II
compartment at day 5 (Fig. 5A) and to signiﬁcant Th1
differentiation when poly I:C was used as adjuvant (Fig. 5B).
Interestingly, a few Foxp3
1 OT-II cells were detected at this early
time point in mice receiving 0.1 or 0.3mgo fa n t i - D N G R - 1
conjugate in the absence of poly I:C (Fig. 5D). The accumulation
of Treg became more obvious at 14 days, when 15–20% of the cells
expressed Foxp3 (Fig. 5C and D). It was accompanied by a
contraction of the OT-II repertoire, greater than the one observed
in mice injected only with PBS or with isotype-matched control
mAb (Fig. 5A). We conclude that antigen targeting to DNGR-1 in
non-inﬂammatory conditions leads to a strong contraction of the
antigen-speciﬁc T-cell compartment and allows the peripheral
conversion of some remaining naı ¨ve T cells into Foxp3
1 Treg.
Discussion
Antigen targeting to DC in vivo is emerging as an attractive
strategy for immunomodulation [3, 4]. Ab-mediated delivery of
antigenic epitopes to DC has variably been shown to allow
priming of CD4
1 and CD8
1 T-cell immunity or to induce
tolerance through deletion or conversion of antigen-speciﬁc
T cell into Treg [3, 4]. An ideal target should be a surface
receptor that delivers the targeting Ab to endocytic and cytosolic
compartments for processing of the linked antigenic moiety and
subsequent (cross)presentation by MHC class I and/or class II
molecules. In addition, it might be desirable to target a ‘‘neutral’’
receptor, i.e. one that does not activate DC upon Ab binding, in
order to be able to induce tolerance or to tune immunity by
co-administering speciﬁc immunomodulators. Finally, the target
receptor should be restricted to DC, in particular to DC subsets
with proved capacity for antigen presentation to T cells. In this
study, we show that DNGR-1 ﬁts all of these criteria. DNGR-1-
targeted antigens are presented to CD4
1 T cells selectively by
CD8a
1 DC without promoting strong Th-cell priming. Adjuvants
can be co-administered to selectively induce Th1 or Th17
responses. In addition, small amounts of DNGR-1-targeted
antigen in the absence of adjuvant can be used to delete
antigen-speciﬁc T cells and promote Treg conversion.
Although CD8a
1 DC have been suggested to be less efﬁcient in
MHC class II antigen presentation than other DC subtypes [21],
this study and many others demonstrate that they are able to
present antigens to CD4
1 Tc e l l sin vivo [8, 26]. They also excel in
antigen crosspresentation to CD8
1 T cells [21, 26, 27] and,
therefore, can concomitantly present antigen to both CD4
1 and
CD8
1 T lymphocytes, allowing optimal delivery of CD4
1 T-cell
help for CTL priming. In addition, as shown here, CD8a
1 DC can
drive the differentiation of Th1 or Th17 cells depending on the
adjuvant. Although the ability of CD8a
1 DC to trigger a Th1
response is well documented, this is the ﬁrst instance when these
cells have been shown to induce Th17 differentiation. These data
Figure 4. Antigen targeting to DNGR-1 leads to Th17 priming when
curdlan is used as adjuvant (A) CFSE-labeled naı ¨ve OT-II cells were
adoptively transferred into B6.SJL hosts. The day after, mice were
immunized with OVA323–339-coupled anti-DNGR-1 mAb in the presence/
absence of 40mg poly I:C or 100mg curdlan. Five days later splenocytes were
restimulated with PMA/ionomycin or OVA323–339 peptide to measure IL-17
and IFN-g production by CD45.2
1 OT-II cells. Analysis was performed
by ﬂow cytometry after intracellular staining (A, B and C left panels).
(A) Representative stainings are shown. The antigen-speciﬁc CD4
1 T-cell
response was also monitored by ELISA after restimulation of splenocytes
for 3 days in the presence of OVA323–339 peptide (B and C, right panels).
(B, C) Data are the mean7SEM of four mice. One representative
experiment out of three performed is shown. The p-values were
determined using unpaired Student’s t-test (p o 0.05, p o 0.001).
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1 DC are not ontogenetically pre-
programmed to induce Th1 responses and highlight the previously
noted importance of innate signals in regulating DC subset func-
tion and instruction of adaptive immune responses [28, 29].
They further suggest that CD8a
1 DC are attractive targets for a
wide range of vaccination approaches designed to promote
immunity to distinct challenges. Interestingly, CD8a
1 DC can
produce large amounts of TGF-b [14]. This ﬁnding may
explain their ability to induce Th17 responses in an inﬂammatory
setting and ﬁts with our previous ﬁnding of TGF-b-dependent
induction of Th17 cells by curdlan-stimulated DC in vitro
[25]. In addition, TGF-b acts to promote the conversion of
naı ¨ve T cells into antigen-speciﬁc Treg in non-inﬂammatory
conditions [14, 30, 31]. This can be seen with small amounts of
DNGR-1-targeted antigen in the absence of adjuvant, in agreement
with previous conclusions that antigen presentation in sub-
immunogenic conditions promotes establishment of tolerance
[12]. Notably, the CD8a
1 DC population includes cells able to
synthesize retinoic acid, which enhances Treg conversion [32]. It is
intriguing to speculate that such cells might be responsible for Treg
conversion following antigen targeting to DNGR-1. The fact that
high doses of antigen and/or strong activation of DC limit Treg
accumulation can be explained by the antagonistic effect of T-cell
proliferation on the Treg conversion process, as previously repor-
ted by Kretschmer et al. upon antigen delivery using anti-DEC205
mAb [12].
Tolerance induction by antigen targeting to DNGR-1 could be
useful in clinical settings for inducing transplantation tolerance
or controlling autoimmunity and could be improved, for exam-
ple, by co-administering immunomodulatory molecules, such as
IL-2 and rapamycin, which expand freshly generated Treg while
selectively dampening down the ‘‘effector’’ population [33]. It is
worth noting that in contrast to the induction of Th1, Th17 or
Foxp3
1 cells, we cannot induce the differentiation of Th2 cells.
This result is in line with the notion that CD8a
1 DC are poor Th2
inducers [34] and ﬁts with recent publications showing that
antigen presentation by DC is not involved in driving Th2
responses [35–37]. Thus, vaccines or immunotherapies employ-
ing antigen targeting to DNGR-1 are unlikely to inadvertently
drive a detrimental allergic Th2 response.
Figure 5. Targeting of small amounts of antigen to DNGR-1 in non-inﬂammatory conditions leads to the differentiation of Foxp3
1 cells. CFSE-
labeled naı ¨ve B6.SJL OT-II cells were adoptively transferred into B6 hosts. The following day, mice were injected with 0.3mgo fO V A 323–339-coupled
isotype-matched control or with indicated amount of OVA323–339-coupled anti-DNGR-1 mAb alone or in combination with 40mg of poly I:C. 5 and 14
days later, (A) the size of the splenic CD45.1
1 compartment and (B) IFN-g production after acute restimulation with OVA323–339 peptide were
determined. (C, D) Foxp3 expression by OT-II cells was also measured by ﬂow cytometry. (C) The ﬂow cytometry proﬁles are representative from the
stainings obtained at day 14. Data are the mean7SEM of 3-9 mice per group from three independent experiments.
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mAb but ﬁnd that poly I:C is by far the most potent inducer of
Th1 priming, in agreement with a recent publication [23].
Notably, double-stranded RNA, such as poly I:C, triggers IL-12
production in DC [38], but it has been reported that IL-12 is
dispensable for Th1 priming when antigen is selectively targeted
to CD8a
1 DC [10]. Our ﬁnding that anti-DNGR-1 conjugates plus
poly I:C prime normal Th1 responses in IL-12 p40-deﬁcient
animals is consistent with that report.
Antigen targeting to some DC-expressed C-type lectin receptor
has been reported to trigger CD4
1 T-cell help-dependent B-cell
responses in the absence of adjuvant [39, 40]. In line with these
observations, Caminschi et al. recently showed that a single
administration of anti-DNGR-1 rat mAb could trigger anti-rat IgG
production, and when the mAb was coupled to OVA protein,
proliferation of OVA-speciﬁc CD4
1 T cells and an anti-OVA IgG
response [17]. In their setting, the co-injection of LPS did not
boost Ab production and the fact that the humoral response had
undergone isotype switching was taken as evidence of CD4
1
T-cell priming, which was conﬁrmed by using T-cell-deﬁcient
mice. When targeting small amounts of antigen to DNGR-1 in the
absence of adjuvant, we are unable to induce immunity as
assessed by antigen-speciﬁc Th1, Th2 or Th17 differentiation or
an anti-rat IgG response. Instead, we found that antigen targeting
to DNGR-1 in the steady state, if anything, leads to Foxp3
1 T-cell
differentiation. This observation is consistent with the fact that
our anti-DNGR-1 antibodies, like those of Caminschi et al., are
unable to trigger detectable phenotypic or functional maturation
of CD8a
1 DC, thought to be a prerequisite for immunity
[4, 9, 17]. With our reagents, inducing an anti-rat IgG response in
the absence of adjuvant was only possible when high amounts of
antigen were injected. But even when pushing the system in that
manner, the response remained 2–3 orders of magnitude lower
than the one induced in the presence of poly I:C. These data
suggest that antigen targeting to DNGR-1 in the absence of
adjuvant might lead to Ab production in certain conditions but
that the process is inefﬁcient and that DC activation by a potent
adjuvant remains important for triggering of a strong humoral
response. Thus, our data largely agree with those of Caminschi
et al. and any differences might be quantitative and reﬂect the use
of distinct targeting antibodies, possibly bearing different afﬁ-
nities for DNGR-1. The major difference between the two studies
is the fact that Caminschi et al. found that the inclusion of
adjuvant did not substantially boost Ab titers, whereas in our
case, we see a massive increase. This discrepancy might be
explained by the fact that Caminschi et al. used LPS, which is a
poor adjuvant in comparison with poly I:C for antigen targeting
approaches in which CD8a
1 DC are the dominant APC (data not
shown and [23]).
It has recently been proposed that human blood lineage-
negative HLA-DR
1 BDCA-3
1 cells may encompass functional
equivalents of mouse CD8a
1 DC in mice [19]. A genome-wide
analysis of the transcriptome of different populations of mouse
and human leukocytes supports this contention [41]. If BDCA-3
1
DC prove to have similar properties to the mouse CD8a
1 DC
population, those cells could become attractive targets for
immune manipulation. In mice, targeting to DEC205 has been
considered as the ‘‘canonical’’ way to direct antigens to CD8a
1
DC. However, there is no evidence that this lectin is expressed on
BDCA-3
1 DC and additionally human DEC205 has been detected
on a large spectrum of hematopoietic cells [3]. Given its highly
restricted pattern of expression [9, 17, 18], its ability to promote
MHC class I crosspresentation and the present demonstration that
DNGR-1 targeting can be useful for manipulation of the CD4
1
T-cell compartment, we envisage that DNGR-1 could constitute a
useful target to selectively deliver antigens to BDCA-3
1 DC and,
by extension, for antigen targeting approaches in human.
Materials and methods
Mice
C57BL/6 (B6), B6.SJL, OT-II, OT-II B6.SJL and clec9a
egfp/egfp [20]
mice were bred at Cancer Research UK in speciﬁc pathogen-free
conditions. For some experiments, B6 mice were obtained from
Charles River. All animal experiments were performed in
accordance with national and institutional guidelines for animal
care.
Reagents
Culture medium was RPMI 1640 supplemented with penicillin,
streptomycin, HEPES, 2-mercaptoethanol, non-essential amino
acids, sodium pyruvate, glutamine (all from Invitrogen) and 10%
heat-inactivated FBS (Bioclear). Poly I:C and curdlan were
obtained from Amersham and Wako, respectively. OVA323–339
peptide was synthesized and puriﬁed by HPLC at Cancer
Research UK. Sterile-ﬁltered egg white was prepared as
previously described [22]. The antibodies used for ELISA, speciﬁc
for mouse IFN-g (R4-6A2 and XMG1.2 clones) and mouse IL-17
(TC11-18H10 and TC11-8H4.1 clones) were obtained from BD.
Flow cytometry
Antibodies speciﬁc for B220 (RA3-6B2), CD62L (MEL-14), CD25
(PC61), CD44 (IM7), CD4 (RM4-5), CD8a (53-6.7), CD11c
(HL3), FcgRIII-II (2.4G2), IFN-g (XMG1.2), Ly-6G and Ly-6C
(RB6-8C5), CD3e (145-2C11) and CD45.2 (104) were obtained
from BD. Anti-CD45.1 (A20), anti-Foxp3 (FJK-16s), anti-FR4
(12A5) and anti-IL-17 (TC11-18H10.1) mAb were purchased
from eBioscience.
Cell suspensions were blocked with 2.4G2, anti-FCgR washed,
resuspended in FACS buffer (PBS, 2mM EDTA, 2% FBS, 0.2%
NaN3) containing the appropriate cocktail of antibodies
and incubated on ice for 20min. For intracellular cytokines
detection, Fix and Perm
s kit (Invitrogen) was used according to
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anti-rat/mouse Foxp3 staining set (eBioscience). Flow cytometry
data were acquired on a FACS Calibur or on a LSR II ﬂow
cytometer (BD) and were analyzed using FlowJo software
(Treestar).
Generation of Ab–antigen conjugates
Anti-DNGR-1 mAb (7H11, rat IgG1) was generated as previously
described [9]. The Avena phytochrome-speciﬁc MAC49 clone was
used as isotype-matched control.
Antibodies were activated with sulfo-SMCC (Pierce) and
puriﬁed by molecular size exclusion chromatography. OVA323–339
peptides, with an added cysteine and biotin at the C-terminus
(Cancer Research UK), were added and the conjugation reaction
was allowed to proceed for 1h. Conjugates were isolated with
GammaBind
TM plus Sepharose
TM (GE Healthcare). Finally, the
number of peptides coupled to each mAb was determined with a
Fluoreporter
s Biotin Quantitation kit (Invitrogen). The molar
ratio between peptides and mAb varied from 1 to 2 but was
systematically adjusted between the two antibodies.
Antigen presentation assay
Mice were injected i.v. with 2mg of OVA323–339-coupled mAb.
Four hours later, or at the indicated time points, splenocytes were
separated into two fractions using anti-CD11c microbeads
(Miltenyi). For further puriﬁcation, CD11c
1 cells were labeled
with mAb speciﬁc for CD11c and CD8a, and the CD11c
1CD8a
 
and CD11c
1CD8a
  fractions were sorted on a MoFlo
TM cell
sorter (Beckman Coulter).
Increasing numbers of APC were co-cultured in round-bottom
96-well plates and in complete medium with 10
5 CFSE-labeled
OT-II cells previously enriched by negative selection using a
cocktail of PE-labeled mAb, anti-PE microbeads (Miltenyi) and
LD columns (Miltenyi). At day 5, CFSE dilution was determined
by ﬂow cytometry. A ﬁxed number of Calibrite
TM beads (BD)
were added to each sample to quantify the absolute number of
OT-II cells per well.
In vivo T-cell priming
Naı ¨ve CD4
1 T cells, deﬁned as CD25
 FR4
 CD62L
brightCD44
low
CD4
1, were puriﬁed from CD4-enriched (Dynal
s Mouse CD4
negative isolation kit, Invitrogen) spleen and total lymph node cells
on a MoFlo
TM or FACSAria
TM (BD) cell sorter. The population was
routinely more than 98% pure and free of Foxp3
1 cells (not
shown). Before transfer, T cells were labeled with 2mMo fC F S E ,
washed and resuspended in PBS. An amount of 1–2 10
6 cells
were adoptively transferred into CD45.1
1 or CD45.2
1 congenic B6
mice. One day later, mice were injected i.v. or in the footpad
with indicated amount of OVA323–339-coupled mAb alone or in
combination with 40mg poly I:C or 100mgc u r d l a n .C D 4
1 T-cell
responses were assessed 4–6 days after immunization or at the
indicated time points. Red-blood-cell-depleted splenocytes were
restimulated in complete medium with either 10mg/mL of
OVA323–339 peptide or 10ng/mL of PMA (Sigma) and 1mg/mL of
ionomycin (Calbiochem). After 30min, Brefeldin A (Sigma) was
added to the culture at a ﬁnal concentration of 10mg/mL,
and the cells were incubated for three more hours. Alternatively,
in some experiments, splenocytes were restimulated for 3 days in
complete medium with or without 10mg/mL of OVA323–339 peptide.
Cytokine accumulation in the supernatant was then monitored by
ELISA.
ELISA detection of anti-rat IgG antibodies
Flat-bottom 96-wells plates (MaxiSorp
TM Nunc-immunoplates)
were coated with 2mg/mL of 7H11 mAb. After overnight incuba-
tion, unbound mAb was washed away (PBS, 0.05% Tween 20) and
non-speciﬁc binding sites were blocked with PBS supplemented with
2.5% FBS and 0.2% NaN3. Serially diluted sera were then plated
and incubated for 6h at room temperature. After six washes, bound
Ab were detected with biotinylated anti-mouse IgG1 (B68-2, BD) or
anti-mouse IgGb
2a(5.7, BD) mAb or with biotin-SP-conjugated anti-
mouse IgG F(ab0)2 (Jackson Immunoresearch). Plates were then
washed extensively and incubated with extravidin
s-conjugated
alkaline phosphatase (Sigma). After six washes, the presence of
bound Ab was revealed using p-Nitrophenyl phosphate (Sigma).
Wells were considered as positive when the value of the absorbance
measured at 405nm was superior to the one obtained with the
serum from a PBS-injected mouse13x SEM. The Ab titer
corresponds to the last dilution scoring positive.
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